Paclitaxel Clinical Trials

3 recruiting

Paclitaxel Trials at a Glance

11 actively recruiting trials for paclitaxel are listed on ClinicalTrialsFinder across 6 cities in 6 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Tianjin, Bangkok, and Bayonne. Lead sponsors running paclitaxel studies include Tianjin Medical University Second Hospital, Department of Medical Services Ministry of Public Health of Thailand, and Chipscreen Biosciences, Ltd..

Browse paclitaxel trials by phase

Treatments under study

About Paclitaxel Clinical Trials

Looking for clinical trials for Paclitaxel? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Paclitaxel trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Paclitaxel clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Phase 1Phase 2

A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma

Metastatic Appendiceal AdenocarcinomaIntraperitoneal Paclitaxel
M.D. Anderson Cancer Center39 enrolled1 locationNCT06207305
Recruiting
Phase 2

Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer

TislelizumabPD-1 InhibitorKidney-sparing+2 more
Tianjin Medical University Second Hospital35 enrolled1 locationNCT07233252
Recruiting
Phase 2

Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC

Neoadjuvant TherapyPD-1 InhibitorUpper Tract Urothelial Carcinoma+1 more
Tianjin Medical University Second Hospital35 enrolled1 locationNCT07126119
Recruiting
Phase 2

Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer

Neoadjuvant TherapyTislelizumabPD-1 Inhibitor+3 more
Tianjin Medical University Second Hospital35 enrolled1 locationNCT07125547
Recruiting
Not Applicable

A Study of the Effect of Real-time Pressure Controllers on Subjective and Objective Symptoms of Peripheral Neuropathy Induced by Albumin Paclitaxel

Breast CancerReal Time Pressure ControllerAlbumin Paclitaxel+1 more
Tianjin Medical University Cancer Institute and Hospital118 enrolled1 locationNCT07019233
Recruiting
Not Applicable

Efficacy of Surgical Glove-Compression Therapy As a Prevention of Paclitaxel-Induced Peripheral Neuropathy

Paclitaxel-induced Peripheral Neuropathy
Department of Medical Services Ministry of Public Health of Thailand36 enrolled1 locationNCT06763575
Recruiting

Investigating Paclitaxel Toxicity in Breast Cancer: the Roles of Physical Activity and Body Composition.

Breast CancerChemotherapeutic ToxicityPaclitaxel Adverse Reaction+3 more
Universitair Ziekenhuis Brussel40 enrolled2 locationsNCT06387901
Recruiting
Phase 3

Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer

Ovarian CancerPaclitaxelRelapsed or Refractory+1 more
Chipscreen Biosciences, Ltd.454 enrolled1 locationNCT04921527
Recruiting
Phase 4

Effect of Alpha Lipoic Acid on Chemotherapy Induced Neurological Changes in Breast Cancer Patients

Breast CancerChemotherapyAlpha Lipoic Acid+2 more
Ain Shams University92 enrolled1 locationNCT06406127
Recruiting

European All-comers' Multicentric Prospective REGISTRY on LUMINOR© Drug Eluting Balloon in the Superficial Femoral Artery and Popliteal Artery With 5 Years Follow-up.

Peripheral Arterial DiseasePaclitaxelAngioplasty+2 more
iVascular S.L.U.500 enrolled15 locationsNCT04743180
Recruiting

Inter-ethnic differences in tolerance of anti-cancer drugs in non-small cell lung cancer patients

tolerance of palliative chemotherapy with carboplatin and paclitaxel in advanced non-small cell lung cancer patients
Sydney Cancer Centre120 enrolled1 locationACTRN12611000013965